MIRM
Neutral signalScored 2026-09-07 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Mirum Pharmaceuticals, Inc.
- Nom
- Mirum Pharmaceuticals, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $5.2B
- Employés
- 433
- PDG
- Christopher Peetz
- Site web
- https://www.mirumpharma.com
- Marché
- AGIOALTARCTENTAMDGLRARE
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 50 000 titres (~4 912 600,00 $ US)
- Insiders
- Peetz Christopher
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$8,212,618
Avg sell (VWAP, 90d window) $99.63 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$3,234,525 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-09-01
- Last synced
-
2026-09-07 10:23:47
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-14 | BJERKHOLT ERIC | Sell · S | 9,943 | $98.37 | $978,093 | Form 4 |
| 2026-09-02 | Howe Jolanda | Sell · S · 10b5-1 | 658 | $100.00 | $65,800 | Form 4 |
| 2026-09-01 | Peetz Christopher | Sell · S · 10b5-1 | 21,688 | $98.91 | $2,145,160 | Form 4 |
| 2026-08-18 | Howe Jolanda | Sell · S | 40,000 | $100.00 | $4,000,000 | Form 4 |
| 2026-08-11 | BJERKHOLT ERIC | Sell · S · 10b5-1 | 6,001 | $99.90 | $599,510 | Form 4 |
| 2026-08-10 | Peetz Christopher | Sell · S · 10b5-1 | 2,300 | $100.14 | $230,322 | Form 4 |
| 2026-08-03 | Howe Jolanda | Sell · S · 10b5-1 | 1,840 | $105.29 | $193,734 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-09-07 Drivers: fundamentals. Moteurs : fondamentaux.
MIRM presents a constructive setup combining solid liquidity (75), improving operational fundamentals (positive EBITDA, narrowing losses), and a meaningful earnings catalyst (Q2 beat + raised 2026 guidance to $680-700M)…
The first sentence of the analysis written for MIRM on 2026-09-07 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Supports a bullish reading. Stored narrative reading is in the bullish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 2.67 · operating margin -4.2% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 80.7% | 75.8% | 74.8% | 83.9% | 90.1% | |
| Ebit Margin | -1.4% | -21.6% | -79.0% | -163.6% | -346.7% | |
| Ebitda Margin | 3.3% | -14.5% | -73.2% | -159.4% | -341.7% | |
| Operating Profit Margin | -4.2% | -26.0% | -58.6% | -170.3% | -906.1% | |
| Pretax Profit Margin | -4.1% | -25.8% | -87.1% | -184.4% | -438.7% | |
| Continuous Operations Profit Margin | -4.5% | -26.1% | -87.7% | -176.0% | -438.9% | |
| Net Profit Margin | -4.5% | -26.1% | -87.7% | -176.0% | -438.9% | |
| Bottom Line Profit Margin | -4.5% | -26.1% | -87.7% | -177.2% | -438.9% | |
| Current Ratio | 2.671 | 3.104 | 4.451 | 2.939 | 3.911 | |
| Quick Ratio | 2.550 | 2.927 | 4.195 | 2.853 | 3.875 | |
| Solvency Ratio | 0.002 | -0.144 | -0.383 | -0.628 | -0.476 | |
| Cash Ratio | 1.442 | 1.758 | 3.289 | 0.433 | 0.736 | |
| Price To Earnings Ratio | -168.064 | -22.351 | -7.380 | -4.863 | -5.758 | |
| Price To Earnings Growth Ratio | 2.253 | 0.416 | 29.594 | -0.109 | 0.178 | |
| Forward Price To Earnings Growth Ratio | 2.253 | 0.416 | 29.594 | -0.109 | 0.178 | |
| Price To Earnings Diluted Ratio | -168.064 | -22.351 | -7.380 | -4.851 | -5.758 | |
| Price To Earnings Diluted Growth Ratio | 2.253 | 0.416 | 14.834 | -0.107 | 0.178 | |
| Price To Book Ratio | 12.600 | 8.709 | 4.854 | 4.646 | 4.023 | |
| Price To Sales Ratio | 7.606 | 5.833 | 6.476 | 8.563 | 25.271 | |
| Price To Free Cash Flow Ratio | 72.261 | 210.574 | -13.255 | -5.480 | -3.186 | |
| Price To Operating Cash Flow Ratio | 71.026 | 190.322 | -17.012 | -5.493 | -3.643 | |
| Debt To Assets Ratio | 0.379 | 0.474 | 0.477 | 0.006 | 0.009 | |
| Debt To Equity Ratio | 1.015 | 1.408 | 1.239 | 0.015 | 0.022 | |
| Debt To Capital Ratio | 0.504 | 0.585 | 0.553 | 0.015 | 0.021 | |
| Long Term Debt To Capital Ratio | 0.496 | 0.577 | 0.552 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 2.678 | 2.973 | 2.600 | 2.485 | 2.451 | |
| Working Capital Turnover Ratio | 1.709 | 1.189 | 0.875 | 0.618 | 0.112 | |
| Operating Cash Flow Ratio | 0.271 | 0.082 | -0.815 | -1.856 | -3.117 | |
| Operating Cash Flow Sales Ratio | 0.107 | 0.031 | -0.381 | -1.559 | -6.937 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.983 | 0.904 | 1.283 | 1.002 | 1.143 | |
| Debt Service Coverage Ratio | 1.061 | -3.494 | -9.102 | -7.288 | -3.719 | |
| Interest Coverage Ratio | -1.538 | -6.122 | -7.226 | -8.212 | -9.859 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.175 | 0.032 | -0.230 | -54.907 | -50.787 | |
| Capital Expenditure Coverage Ratio | 58.519 | 10.398 | -3.528 | -432.144 | -6.978 | |
| Dividend Paid And Capex Coverage Ratio | 58.519 | 10.398 | -3.528 | -432.144 | -6.978 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 231.776 | -42.072 | -9.002 | -5.161 | -6.957 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 80.7% | ▲4.9% | ▼-0.3% |
| Ebit Margin | -1.4% | ▲20.2% | ▲121.1% |
| Ebitda Margin | 3.3% | ▲17.8% | ▲120.4% |
| Operating Profit Margin | -4.2% | ▲21.8% | ▲228.8% |
| Pretax Profit Margin | -4.1% | ▲21.7% | ▲143.9% |
| Continuous Operations Profit Margin | -4.5% | ▲21.6% | ▲142.2% |
| Net Profit Margin | -4.5% | ▲21.6% | ▲142.2% |
| Bottom Line Profit Margin | -4.5% | ▲21.6% | ▲142.4% |
| Current Ratio | 2.671 | ▼-0.433 | ▼-0.744 |
| Quick Ratio | 2.550 | ▼-0.377 | ▼-0.730 |
| Solvency Ratio | 0.002 | ▲0.146 | ▲0.328 |
| Cash Ratio | 1.442 | ▼-0.317 | ▼-0.090 |
| Price To Earnings Ratio | -168.064 | ▼-145.713 | ▼-126.381 |
| Price To Earnings Growth Ratio | 2.253 | ▲1.837 | ▼-4.213 |
| Forward Price To Earnings Growth Ratio | 2.253 | ▲1.837 | ▼-4.213 |
| Price To Earnings Diluted Ratio | -168.064 | ▼-145.713 | ▼-126.383 |
| Price To Earnings Diluted Growth Ratio | 2.253 | ▲1.837 | ▼-1.262 |
| Price To Book Ratio | 12.600 | ▲3.891 | ▲5.634 |
| Price To Sales Ratio | 7.606 | ▲1.773 | ▼-3.144 |
| Price To Free Cash Flow Ratio | 72.261 | ▼-138.313 | ▲20.078 |
| Price To Operating Cash Flow Ratio | 71.026 | ▼-119.296 | ▲23.986 |
| Debt To Assets Ratio | 0.379 | ▼-0.095 | ▲0.110 |
| Debt To Equity Ratio | 1.015 | ▼-0.393 | ▲0.275 |
| Debt To Capital Ratio | 0.504 | ▼-0.081 | ▲0.168 |
| Long Term Debt To Capital Ratio | 0.496 | ▼-0.081 | ▲0.171 |
| Financial Leverage Ratio | 2.678 | ▼-0.294 | ▲0.041 |
| Working Capital Turnover Ratio | 1.709 | ▲0.520 | ▲0.808 |
| Operating Cash Flow Ratio | 0.271 | ▲0.190 | ▲1.358 |
| Operating Cash Flow Sales Ratio | 0.107 | ▲0.076 | ▲1.855 |
| Free Cash Flow Operating Cash Flow Ratio | 0.983 | ▲0.079 | ▼-0.080 |
| Debt Service Coverage Ratio | 1.061 | ▲4.555 | ▲5.569 |
| Interest Coverage Ratio | -1.538 | ▲4.583 | ▲5.053 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | 0.175 | ▲0.142 | ▲21.318 |
| Capital Expenditure Coverage Ratio | 58.519 | ▲48.121 | ▲133.266 |
| Dividend Paid And Capex Coverage Ratio | 58.519 | ▲48.121 | ▲133.266 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 231.776 | ▲273.847 | ▲198.059 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $3.97B | $1.97B | $1.21B | $659.9M | $483.6M | |
| Enterprise value | $3.99B | $2.06B | $1.23B | $634.0M | $454.9M | |
| EV / Sales | 7.65x | 6.12x | 6.59x | 8.23x | 23.77x | |
| EV / Op. cash flow | 71.43x | 199.55x | -17.32x | -5.28x | -3.43x | |
| EV / Free cash flow | 72.68x | 220.78x | -13.49x | -5.27x | -3.00x | |
| EV / EBITDA | 231.78x | -42.07x | -9.00x | -5.16x | -6.96x | |
| Net debt / EBITDA | 1.32x | -1.95x | -0.16x | 0.21x | 0.44x | |
| Current ratio | 2.67x | 3.10x | 4.45x | 2.94x | 3.91x | |
| Income quality | -2.39x | -0.12x | 0.43x | 0.89x | 1.58x | |
| Graham net-net | -$1 | -$2 | -$1 | -$1 | -$0 | |
| Tax burden | 109.0% | 101.2% | 100.6% | 95.5% | 100.0% | |
| Interest burden | 304.4% | 119.7% | 110.3% | 112.7% | 126.5% | |
| Working capital | $343.9M | $266.2M | $300.5M | $125.5M | $124.0M | |
| Invested capital | $615.4M | $525.9M | $555.4M | $186.8M | $145.3M | |
| Return on assets | -2.8% | -13.1% | -25.3% | -38.4% | -28.5% | |
| Operating ROA | -2.9% | -13.3% | -21.8% | -40.5% | -64.8% | |
| Return on tangible assets | -4.0% | -20.9% | -41.5% | -46.2% | -30.4% | |
| Return on equity | -7.4% | -39.0% | -65.7% | -95.5% | -69.9% | |
| Return on invested capital | -3.5% | -16.0% | -19.5% | -43.3% | -68.6% | |
| Return on capital employed | -3.5% | -16.1% | -19.5% | -45.5% | -68.8% | |
| Earnings yield | -0.6% | -4.5% | -13.5% | -20.6% | -17.4% | |
| Free cash flow yield | 1.4% | 0.5% | -7.5% | -18.2% | -31.4% | |
| Capex / Op. cash flow | 1.7% | 9.6% | -28.3% | -0.2% | -14.3% | |
| Capex / Depreciation | 3.9% | 4.2% | 185.7% | 7.6% | 1951.2% | |
| Capex / Sales | 0.2% | 0.3% | 10.8% | 0.4% | 99.4% | |
| SG&A / Sales | 49.3% | 60.0% | 78.3% | 115.6% | 309.4% | |
| R&D / Sales | 35.7% | 41.7% | 55.1% | 138.6% | 686.7% | |
| Stock comp / Sales | 13.7% | 14.4% | 18.8% | 35.0% | 120.6% | |
| Intangibles / Total assets | 31.0% | 37.2% | 39.1% | 16.7% | 6.4% | |
| Days sales outstanding | 86d | 85d | 133d | 114d | 83d | |
| Days payables outstanding | 35d | 65d | 58d | 256d | 1758d | |
| Operating cycle | 177d | 185d | 306d | 278d | 373d | |
| Cash conversion cycle | 142d | 120d | 249d | 21d | -1385d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-09-04 Why Is Mirum Pharmaceuticals (MIRM) Up 6.9% Since Last Earnings Report? Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What''s next for the stock?
- 2026-09-02 Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences.
- 2026-08-25 BlackRock Inc. Takes $513.95 Million Position in Mirum Pharmaceuticals, Inc. $MIRM BlackRock Inc. purchased a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) in the undefined quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 4,390,063 shares of the company''s stock, valued at approximately $513,945,000. BlackRock Inc. owned about 7.20% of Mirum Pharmaceuticals at the end
- 2026-08-24 Deutsche Bank AG Purchases New Holdings in Mirum Pharmaceuticals, Inc. $MIRM Deutsche Bank AG acquired a new position in Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 81,586 shares of the company''s stock, valued at approximately $9,551,000. Deutsche Bank AG owned 0.13% of Mirum Pharmaceuticals at the end
- 2026-08-11 Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
- 2026-08-06 Mirum''s Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised MIRM Q2 earnings miss estimates while revenues beat the same, as Livmarli and bile acid drugs fuel growth, prompting a higher 2026 sales outlook.
- 2026-08-05 Mirum Pharmaceuticals, Inc. (MIRM) Q2 2026 Earnings Call Transcript Mirum Pharmaceuticals, Inc. (MIRM) Q2 2026 Earnings Call Transcript
- 2026-08-05 Mirum Pharmaceuticals Q2 Earnings Call Highlights Mirum Pharmaceuticals NASDAQ: MIRM reported second-quarter net product sales of $176 million and raised its full-year 2026 product sales outlook to $680 million to $700 million, while outlining several upcoming clinical and regulatory milestones across its rare liver and rare genetic disease portfolios.
- 2026-08-05 Compared to Estimates, Mirum Pharmaceuticals (MIRM) Q2 Earnings: A Look at Key Metrics The headline numbers for Mirum Pharmaceuticals (MIRM) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 2026-08-05 Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Beats Revenue Estimates Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.8 per share versus the Zacks Consensus Estimate of a loss of $0.77. This compares to a loss of $0.12 per share a year ago.